Skip to main content
Erschienen in: Medical Oncology 2/2010

01.06.2010 | Letter to the Editor

Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates

verfasst von: Sercan Aksoy, Omer Dizdar, Kadri Altundag

Erschienen in: Medical Oncology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …
Literatur
1.
Zurück zum Zitat Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A, et al.. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Med Oncol. 2009 Mar 28 [Epub ahead of print]. Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A, et al.. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Med Oncol. 2009 Mar 28 [Epub ahead of print].
2.
Zurück zum Zitat Dincer M, Altundag K, Harputluoglu H, Aksoy S, Cengiz M, Gullu I. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol. 2008;25:356–9. doi:10.1007/s12032-008-9045-3.CrossRefPubMed Dincer M, Altundag K, Harputluoglu H, Aksoy S, Cengiz M, Gullu I. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol. 2008;25:356–9. doi:10.​1007/​s12032-008-9045-3.CrossRefPubMed
3.
Zurück zum Zitat Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36. doi:10.1359/jbmr.080205.CrossRefPubMed Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36. doi:10.​1359/​jbmr.​080205.CrossRefPubMed
Metadaten
Titel
Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates
verfasst von
Sercan Aksoy
Omer Dizdar
Kadri Altundag
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2010
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9236-6

Weitere Artikel der Ausgabe 2/2010

Medical Oncology 2/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.